Pelacarsen Roll-over Extension Program

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 599 participants.

Also called NCT06875973

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 599 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06875973
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06875973. Allocation not applicable; no masking; primary purpose treatment. Start 2025-05-19 (actual); primary completion 2030-12-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pelacarsen Roll-over Extension Program
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Pelacarsen (TQJ230)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06875973
Content hash
1d05c704d12db076f7d428c3bcc5ab1043d1e2abcefa962d7657edd59459d880